Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma

NCT01570049 is registered in ClinicalTrials.gov with Shandong Lanjin Pharmaceuticals Co.,Ltd as lead sponsor.

NCT NCT01570049
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01570049 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter, Single Arm Clinical Trial in Patients With Rituximab Refractory B-cell Indolent Lymphoma
Lead sponsor
Shandong Lanjin Pharmaceuticals Co.,Ltd
Phase
Phase 3
Overall status
Unknown status
Start date
April 30, 2010
Completion date
December 31, 2012
Enrollment
100 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

non-hodgkin lymphoma by clinical course